文献速递关节外科

抗菌涂层在全关节置换术后第一年医疗成本中的经济学评价

Economic Evaluation of Antibacterial Coatings on Healthcare Costs in First Year Following Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2018-02-10

本研究评估三种抗菌涂层(双抗生素骨水泥COPAL G+C、抗菌水凝胶涂层DAC、银涂层Agluna)在全关节置换术后第一年的经济平衡点及潜在年度医疗成本节约。结果显示三者在术后感染率分别为1.5%、2.6%和19.2%的患者人群中达到经济平衡;

要点

  • COPAL G+C、DAC和Agluna术后第一年经济平衡点对应感染率分别为1.5%、2.6%和19.2%。
  • 预期感染率5%人群中,COPAL G+C和DAC每年分别节约约4880万和4320万欧元。

核心结论

  • 经济学评价显示,抗菌涂层技术主要通过降低手术部位感染发生率来潜在地减少医疗成本,前提是該技术用于适当风险等级的患者人群。

研究设计与样本

  • 本研究为经济学评价,基于算法纳入的变量包括平均成本与初次关节置换数量、每患者抗菌涂层平均成本、假体周围关节感染发生率及使用抗菌涂层后的预期降低幅度、感染治疗平均成本及预期病例数。

主要发现

  • COPAL G+C、DAC和Agluna在术后第一年的经济平衡点分别在预期术后感染率为1.5%、2.6%和19.2%的患者人群中达到。
  • 若在全国范围应用于预期术后感染率5%的中高风险人群,COPAL G+C和DAC水凝胶涂层每年直接成本节约分别约为48,800,000欧元和43,200,000欧元(每患者分别为1220欧元和1080欧元)。
  • 同一人群中使用银涂层Agluna则与约136,000,000欧元的经济损失相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibacterial coatings (ABCs) of implants have proven safe and effective to reduce postsurgical infection, but little is known about their possible economic impact on large-scale use. This study evaluated the point of economic balance, during the first year after surgery, and the potential overall annual healthcare cost savings of 3 different antibacterial technologies applied to joint arthroplasty: a dual-antibiotic-loaded bone cement (COPAL G + C), an antibacterial hydrogel coating (DAC), and a silver coating (Agluna). METHODS: The variables included in the algorithm were average cost and number of primary joint arthroplasties; average cost per patient of the ABC; incidence of periprosthetic joint infections and expected reduction using the ABCs; average cost of infection treatment and expected number of cases. RESULTS: The point of economic balance for COPAL G + C, DAC, and Agluna in the first year after surgery was reached in patient populations with an expected postsurgical infection rate of 1.5%, 2.6%, and 19.2%, respectively. If applied on a national scale, in a moderately high-risk population of patients with a 5% expected postsurgical infection rate, COPAL G + C and DAC hydrogel would provide annual direct cost savings of approximately €48,800,000 and €43,200,000 (€1220 and €1080 per patient), respectively, while the silver coating would be associated with an economic loss of approximately €136,000,000. CONCLUSION: This economic evaluation shows that ABC technologies have the potential to decrease healthcare costs primarily by decreasing the incidence of surgical site infections, provided that the technology is used in the appropriate risk class of patients.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Trentinaglia MT, Van Der Straeten C, Morelli I, et al. Economic Evaluation of Antibacterial Coatings on Healthcare Costs in First Year Following Total Joint Arthroplasty. J Arthroplasty. 2018. PMID: 29530518. doi:10.1016/j.arth.2018.01.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。